Literature DB >> 33680092

Candidate Genes Identified in Systemic Sclerosis-Related Pulmonary Arterial Hypertension Were Associated with Immunity, Inflammation, and Cytokines.

Zhixiao Xu1, Jiaxing Ruan1, Lingyun Pan1, Chengshui Chen1,2.   

Abstract

BACKGROUND: Pulmonary complications of systemic sclerosis (SSc), including pulmonary arterial hypertension (PAH), are the leading causes of patient death. However, the precise molecular mechanisms of its etiology are unclear. This study's objective was to identify the candidate genes involved in the progression of SSc-PAH and investigate the genes' function.
METHODS: The gene expression profiles of GSE33463 were obtained from the Gene Expression Omnibus (GEO) database. A free-scale gene coexpression network was constructed using the weighted gene coexpression network analysis (WGCNA) to explore the association between gene sets and clinical features and identify candidate biomarkers. Then, gene ontology analysis was performed. A second dataset was used, GSE19617, to validate the hub genes. The verified hub genes' potential function was further explored using gene set enrichment analysis (GSEA).
RESULTS: Through average link-level clustering, a total of seven modules were classified. A total of 938 hub genes were identified in the key module, and the key module's function mainly enriched was related to chemokine activities. Subsequently, four candidate genes, BTG3, CCR2, RAB10, and TMEM60, were filtered. The expression levels of these four hub genes were consistent in the GSE19617 and GSE33463 datasets. We plotted the ROC curve of the hub genes (all AUC > 0.70). Furthermore, the results of the GSEA for hub genes were correlated with complement and inflammatory responses.
CONCLUSIONS: The hub genes (BTG3, CCR2, RAB10, and TMEM60) performed well in distinguishing the SSc-PAH patients from controls, and some biological functions, related to immunity, inflammation, and cytokines, might pave the way for follow-up studies on the diagnosis and treatment of SSc-PAH.
Copyright © 2021 Zhixiao Xu et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33680092      PMCID: PMC7906811          DOI: 10.1155/2021/6651009

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  34 in total

1.  clusterProfiler: an R package for comparing biological themes among gene clusters.

Authors:  Guangchuang Yu; Li-Gen Wang; Yanyan Han; Qing-Yu He
Journal:  OMICS       Date:  2012-03-28

2.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

Review 3.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; Elvira Stacher; Jeffrey Robinson; Rahul Kumar; Brian B Graham
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

Review 4.  Genetics of vasculitis.

Authors:  Francisco David Carmona; Javier Martín; Miguel A González-Gay
Journal:  Curr Opin Rheumatol       Date:  2015-01       Impact factor: 5.006

5.  Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.

Authors:  Yuhu He; Caojian Zuo; Daile Jia; Peiyuan Bai; Deping Kong; Di Chen; Guizhu Liu; Juanjuan Li; Yuanyang Wang; Guilin Chen; Shuai Yan; Bing Xiao; Jian Zhang; Lingjuan Piao; Yanli Li; Yi Deng; Bin Li; Philippe P Roux; Katrin I Andreasson; Richard M Breyer; Yunchao Su; Jian Wang; Ankang Lyu; Yujun Shen; Ying Yu
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

6.  Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression.

Authors:  Chuanbo Zhang; Debyani Chakravarty; Isamu Sakabe; Rajshree R Mewani; Howard E Boudreau; Deepak Kumar; Imran Ahmad; Usha N Kasid
Journal:  Mol Ther       Date:  2006-02-07       Impact factor: 11.454

7.  CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension.

Authors:  Yen-Rei A Yu; Lan Mao; Claude A Piantadosi; Michael D Gunn
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

8.  Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury.

Authors:  Sarah A Pendergrass; Everett Hayes; Giuseppina Farina; Raphael Lemaire; Harrison W Farber; Michael L Whitfield; Robert Lafyatis
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

9.  Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).

Authors:  Kathleen D Kolstad; Shufeng Li; Virginia Steen; Lorinda Chung
Journal:  Chest       Date:  2018-05-16       Impact factor: 9.410

Review 10.  Evaluation and management approaches for scleroderma lung disease.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Ther Adv Respir Dis       Date:  2017-06-16       Impact factor: 4.031

View more
  3 in total

Review 1.  Connections for Matters of the Heart: Network Medicine in Cardiovascular Diseases.

Authors:  Abhijeet Rajendra Sonawane; Elena Aikawa; Masanori Aikawa
Journal:  Front Cardiovasc Med       Date:  2022-05-19

2.  Stress Reactivity, Susceptibility to Hypertension, and Differential Expression of Genes in Hypertensive Compared to Normotensive Patients.

Authors:  Dmitry Oshchepkov; Irina Chadaeva; Rimma Kozhemyakina; Karina Zolotareva; Bato Khandaev; Ekaterina Sharypova; Petr Ponomarenko; Anton Bogomolov; Natalya V Klimova; Svetlana Shikhevich; Olga Redina; Nataliya G Kolosova; Maria Nazarenko; Nikolay A Kolchanov; Arcady Markel; Mikhail Ponomarenko
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

3.  Integrated analysis of m6A mRNA methylation in rats with monocrotaline-induced pulmonary arterial hypertension.

Authors:  Yunhong Zeng; Ting Huang; Wanyun Zuo; Dan Wang; Yonghui Xie; Xun Wang; Zhenghui Xiao; Zhi Chen; Qiming Liu; Na Liu; Yunbin Xiao
Journal:  Aging (Albany NY)       Date:  2021-07-26       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.